Which has higher valuation and earnings, DYN or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is DYN or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media prefer DYN or CRVS?

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Dyne Therapeutics. MarketBeat recorded 10 mentions for Corvus Pharmaceuticals and 9 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.76 beat Corvus Pharmaceuticals' score of 1.30 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Corvus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRVS or ACAD?

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 10 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.30 beat ACADIA Pharmaceuticals' score of 1.16 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, CRVS or EWTX?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is CRVS or EWTX more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% Edgewise Therapeutics N/A -39.01% -36.96%

Does the media favor CRVS or EWTX?

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 10 articles in the media. Edgewise Therapeutics' average media sentiment score of 1.59 beat Corvus Pharmaceuticals' score of 1.30 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, CELC or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is CELC or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media favor CELC or CRVS?

In the previous week, Celcuity and Celcuity both had 10 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.30 beat Celcuity's score of 1.20 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, PBLS or CRVS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A

Is PBLS or CRVS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Parabilis Medicines N/A N/A N/A Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media prefer PBLS or CRVS?

In the previous week, Parabilis Medicines and Parabilis Medicines both had 10 articles in the media. Parabilis Medicines' average media sentiment score of 1.31 beat Corvus Pharmaceuticals' score of 1.30 indicating that Parabilis Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Corvus Pharmaceuticals (CRVS) Competitors

$14.16 -0.56 (-3.80%)

As of 08/28/2026 04:00 PM Eastern

Compare

CRVS vs. DYN, ACAD, EWTX, CELC, and PBLS

Should you buy Corvus Pharmaceuticals stock or one of its competitors? Corvus Pharmaceuticals's main competitors and comparable companies include Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), Celcuity (CELC), and Parabilis Medicines (PBLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Corvus Pharmaceuticals compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Dyne Therapeutics. MarketBeat recorded 10 mentions for Corvus Pharmaceuticals and 9 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.76 beat Corvus Pharmaceuticals' score of 1.30 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Corvus Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyne Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Corvus Pharmaceuticals' return on equity of -36.15% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Dyne Therapeutics presently has a consensus price target of $34.42, indicating a potential upside of 37.28%. Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 135.40%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Corvus Pharmaceuticals beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Corvus Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
ACADIA Pharmaceuticals	$1.07B	4.68	$391M	$2.22	13.11

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 10 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.30 beat ACADIA Pharmaceuticals' score of 1.16 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals presently has a consensus target price of $33.33, suggesting a potential upside of 135.40%. ACADIA Pharmaceuticals has a consensus target price of $34.36, suggesting a potential upside of 18.04%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Corvus Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Corvus Pharmaceuticals' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Summary

ACADIA Pharmaceuticals beats Corvus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Edgewise Therapeutics?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, suggesting a potential upside of 135.40%. Edgewise Therapeutics has a consensus target price of $50.33, suggesting a potential upside of 17.71%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Corvus Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 10 articles in the media. Edgewise Therapeutics' average media sentiment score of 1.59 beat Corvus Pharmaceuticals' score of 1.30 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Corvus Pharmaceuticals' return on equity of -36.15% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Summary

Corvus Pharmaceuticals beats Edgewise Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Celcuity?

Celcuity (NASDAQ:CELC) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

63.3% of Celcuity shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Celcuity currently has a consensus price target of $154.55, suggesting a potential upside of 74.75%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 135.40%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Celcuity has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

In the previous week, Celcuity and Celcuity both had 10 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.30 beat Celcuity's score of 1.20 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals' return on equity of -36.15% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Summary

Corvus Pharmaceuticals beats Celcuity on 10 of the 13 factors compared between the two stocks.

How does Corvus Pharmaceuticals compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Parabilis Medicines' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

In the previous week, Parabilis Medicines and Parabilis Medicines both had 10 articles in the media. Parabilis Medicines' average media sentiment score of 1.31 beat Corvus Pharmaceuticals' score of 1.30 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Parabilis Medicines currently has a consensus target price of $41.67, indicating a potential upside of 6.54%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 135.40%. Given Corvus Pharmaceuticals' higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Parabilis Medicines and Corvus Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

Get Corvus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVS vs. The Competition

Export

Metric	Corvus Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.19B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-23.21	11.62	273.16	25.45
Price / Sales	N/A	1,295.87	605.06	76.64
Price / Cash	111.71	106.39	76.74	53.00
Price / Book	5.28	16.53	12.98	6.14
Net Income	-$15.28M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-2.07%	-0.31%	0.13%	-0.80%
1 Month Performance	7.35%	9.80%	7.08%	4.13%
1 Year Performance	146.69%	55.66%	24.67%	15.17%

Corvus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVS Corvus Pharmaceuticals	3.1408 of 5 stars	$14.16 -3.8%	$33.33 +135.4%	+146.7%	$1.19B	N/A	N/A	30	News Coverage Positive News
DYN Dyne Therapeutics	3.7073 of 5 stars	$26.00 -0.6%	$34.42 +32.4%	+85.8%	$4.88B	N/A	N/A	100	Positive News
ACAD ACADIA Pharmaceuticals	4.6828 of 5 stars	$30.18 +4.0%	$34.19 +13.3%	+12.0%	$4.87B	$1.07B	13.59	510	Positive News Analyst Forecast
EWTX Edgewise Therapeutics	3.3493 of 5 stars	$44.11 +0.2%	$49.08 +11.3%	+198.0%	$4.80B	N/A	N/A	60	News Coverage Positive News
CELC Celcuity	2.7597 of 5 stars	$93.24 +0.9%	$154.55 +65.8%	+72.6%	$4.49B	N/A	N/A	40	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVS) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. DYN, ACAD, EWTX, CELC, and PBLS

How does Corvus Pharmaceuticals compare to Dyne Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does Corvus Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Corvus Pharmaceuticals compare to Celcuity?

Summary

How does Corvus Pharmaceuticals compare to Parabilis Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corvus Pharmaceuticals (CRVS) Competitors

CRVS vs. DYN, ACAD, EWTX, CELC, and PBLS

How does Corvus Pharmaceuticals compare to Dyne Therapeutics?

Does the media prefer DYN or CRVS?

Which has more risk and volatility, DYN or CRVS?

Which has higher valuation and earnings, DYN or CRVS?

Is DYN or CRVS more profitable?

Do analysts prefer DYN or CRVS?

Do insiders and institutionals believe in DYN or CRVS?

Summary

How does Corvus Pharmaceuticals compare to ACADIA Pharmaceuticals?

Which has more risk & volatility, CRVS or ACAD?

Do insiders & institutionals believe in CRVS or ACAD?

Which has better earnings & valuation, CRVS or ACAD?

Does the media refer more to CRVS or ACAD?

Do analysts prefer CRVS or ACAD?

Is CRVS or ACAD more profitable?

Summary

How does Corvus Pharmaceuticals compare to Edgewise Therapeutics?

Do analysts rate CRVS or EWTX?

Which has more risk and volatility, CRVS or EWTX?

Do insiders and institutionals hold more shares of CRVS or EWTX?

Does the media favor CRVS or EWTX?

Which has better earnings & valuation, CRVS or EWTX?

Is CRVS or EWTX more profitable?

Summary

How does Corvus Pharmaceuticals compare to Celcuity?

Which has better valuation and earnings, CELC or CRVS?

Do insiders & institutionals hold more shares of CELC or CRVS?

Do analysts recommend CELC or CRVS?

Which has more volatility & risk, CELC or CRVS?

Does the media favor CELC or CRVS?

Is CELC or CRVS more profitable?

Summary

How does Corvus Pharmaceuticals compare to Parabilis Medicines?

Is PBLS or CRVS more profitable?

Which has higher earnings & valuation, PBLS or CRVS?

Does the media prefer PBLS or CRVS?

Do insiders and institutionals believe in PBLS or CRVS?

Do analysts rate PBLS or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS vs. The Competition

Corvus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools